Labcorp expands Medidata accord with eye on decentralized trials
Labcorp has extended its biomarker and decentralized trial development deal with Medidata.
The move was announced last week with chief scientific officer Bill Hanlon framing it as an expansion of Labcorp’s offering.
“Our relationship with Medidata is built on using their core technologies to enhance our clinical trial portfolio and continue to expand our decentralized clinical trial offerings.
“Our work to advance sensor and digital biomarker usage in clinical research can help accelerate patient care while providing valuable information to study sponsors.”
This was echoed by Medidata CEO Anthony Costello, who set the agreement in the context of growing industry interest in decentralized trials as a result of the pandemic.
“The last two years have required clinical trials to become more accessible and flexible; these changes make our strategic partnership with Labcorp Drug Development to modernize and decentralize trials even more critical.
“With this new agreement, we’re excited to develop and deploy the innovations that help our customers run more effective clinical programs and get new treatments to patients faster than ever before.”
The firms have worked together for more than a decade with Labcorp using several of Medidata’s technologies as part of its trial services offering to the drug industry.
In 2021, Labcorp started using Medidata’s sensor cloud in an agreement that involved the tech firm processing medical-grade sensor data within drug, vaccine and device trials across Labcorp Drug Development’s clinical trial portfolio.
News of the extension follows hot on the heels of a similar move by Parexel, which strengthened an existing accord with Medidata in a bid to build its decentralized and hybrid clinical trial offering.
And, a few months prior, Circuit Clinical, a specialist CRO, extended its agreement with Medidata also citing decentralized trials as the motivation.
The Labcorp announcement also comes just a month after Medidata opened it “patient centricity by design” process up to sponsors, contract research organizations (CROs) and clinical trial sites.
Image: iStock/Zerbor